Ireland-headquartered Shire (LSE: SHP) has announced changes to its executive committee, as it progresses its strategy to sharpen its focus as a leader in rare diseases.
Jeff Poulton, chief financial officer, will be leaving Shire at the end of the year to serve as CFO at Indigo Ag, a start-up company based in Boston that uses the plant microbiome to improve the productivity and sustainability of agriculture. The board will commence a formal search for a successor and Mr Poulton will continue to serve in his current role as this search progresses.
Dr Flemming Ornskov, chief executive of Shire, said: “It is with regret that we announce Jeff’s upcoming departure. Having held numerous roles within the company, Jeff has demonstrated steadfast commitment to Shire through a very intense period of activity and has made significant contributions to our organization. Jeff will continue to lead the Shire Finance team through the Q3 reporting period and to the end of the year, and will play an active role in the search for his successor. On behalf of all Shire employees, we are grateful to Jeff for his dedication and leadership and wish him the very best in his future endeavours.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze